Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

Journal of Thrombosis and Thrombolysis
S Michael GharacholouAmish N Raval

Abstract

Strong evidence exists in favor of rapid transfer of a patient suffering an ST-elevation myocardial infarction (STEMI) to the nearest hospital with primary percutaneous coronary intervention (PCI) capability, assuming the time from first medical contact to balloon inflation can be achieved in less than 90 min. In many areas, PCI hospitals have successfully collaborated with regional non-PCI hospitals to provide primary PCI for STEMI; however, significant variations exist in how these programs are executed. For example, the pre PCI hospital administration of antithrombotic agents by emergency medical personnel can include aspirin, clopidogrel, unfractionated heparin, low molecular weight heparin, partial or full dose fibrinolytics or combinations thereof. There is little consensus on the optimal cocktail, dose and route of administration. Standardizing the pre PCI antithrombotic regimen across hospital systems may be one approach to improve timely administration of these therapies, and potentially improve STEMI outcomes.

References

May 5, 1994·The New England Journal of Medicine·C Patrono
Jul 22, 1996·Archives of Internal Medicine·M J Eisenberg, E J Topal
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Aug 22, 2003·The New England Journal of Medicine·Henning R AndersenUNKNOWN DANAMI-2 Investigators
Mar 11, 2005·The New England Journal of Medicine·Marc S SabatineUNKNOWN CLARITY-TIMI 28 Investigators
Sep 7, 2005·JAMA : the Journal of the American Medical Association·Marc S SabatineUNKNOWN Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Dec 29, 2005·JAMA : the Journal of the American Medical Association·Karen P AlexanderUNKNOWN CRUSADE Investigators
Feb 21, 2006·Lancet·UNKNOWN Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) inv
Mar 16, 2006·The New England Journal of Medicine·Elliott M AntmanUNKNOWN ExTRACT-TIMI 25 Investigators
Mar 16, 2006·JAMA : the Journal of the American Medical Association·Salim YusufUNKNOWN OASIS-6 Trial Group
Mar 30, 2006·Circulation·Alice K JacobsUNKNOWN American Heart Association's Acute Myocardial Infarction Advisory Working Group
Apr 4, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nagy A FaridMark J Goldberg
Sep 4, 2007·Journal of the American College of Cardiology·William E BodenChristopher B Granger
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Nov 6, 2007·The New England Journal of Medicine·Deepak L Bhatt
Nov 6, 2007·JAMA : the Journal of the American Medical Association·James G JollisUNKNOWN Reperfusion of Acute Myocardial Infarction in North Carolina Emergency Departments (RACE) Investigators
May 24, 2008·The New England Journal of Medicine·Stephen G EllisUNKNOWN FINESSE Investigators
May 24, 2008·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Apr 11, 2009·Journal of the American College of Cardiology·Nihar R DesaiMarc S Sabatine
Jun 26, 2009·The New England Journal of Medicine·Warren J CantorUNKNOWN TRANSFER-AMI Trial Investigators
Aug 27, 2009·JAMA : the Journal of the American Medical Association·Alan R ShuldinerPaul A Gurbel
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén

❮ Previous
Next ❯

Citations

Oct 1, 2018·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Rahman ShahSunil V Rao
Feb 6, 2017·Journal of the American Heart Association·Sverrir I GunnarssonAmish N Raval

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.